Decitabine + ARSENIC TRIOXIDE for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 May 2008: Trial registered, NCT00671697

The trials

NCT00671697: Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

State
Completed
Phase
Phase 1
People
13 taking part
Started
May 2008
Primary completion
Jan 2010
Arms
Dose Level 1 Arsenic Trioxide & Decitabine, Dose Level 2 Arsenic Trioxide & Decitabine, Dose Level 3 Arsenic Trioxide & Decitabine
Results
None posted
  1. 5 May 2008: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.